Active Biotech AB Interim report January - March 2016

Laquinimod
· The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market approval in the US and Europe, is proceeding according to plan. Study results are expected in the first half of 2017
· The clinical Phase 2 study ARPEGGIO for the treatment of primary progressive multiple sclerosis (PPMS) is proceeding according to plan
· The clinical Phase 2 study LEGATO-HD for the treatment of Huntington's disease is proceeding according to plan
· Extension studies with 0.6 mg laquinimod in patients from the Phase 3 studies ALLEGRO and BRAVO are proceeding according to plan
· As earlier communicated the highest dose groups in the clinical studies CONCERTO, ARPEGGIO and LEGATO-HD have been discontinued due to cardiovascular events

Tasquinimod     
· In March 2016, it was announced that the company plans to develop tasquinimod to treat multiple myeloma and intends to seek a collaboration partner for the project
· An expanded analysis of the secondary endpoints in the 10TASQ10 study was presented at the ASCO GU Symposium in January 2016. The results showed that tasquinimod had positive effects on both radiographic and PSA-based endpoints. However, as previously communicated, overall survival (OS) was not extended, prompting the discontinuation of all further development within prostate cancer

ANYARA, Paquinimod (57-57) and SILC (ISI)
· Out-licensing activities are continuing

Financial summary

For further information, please contact: 

Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
  
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
                                                                 
The report is also available at www.activebiotech.com.